In this issue:
Antenatal HBV care predicts timely HBIg administration
Low-level viraemia during entecavir: HCC risk
HBV reactivation risk when treating haematological malignancies
Sofosbuvir, velpatasvir + voxilaprevir after DAA failure in HCV
Lower CV risk with chronic HBV vs no HBV in diabetic patients?
Grazoprevir + ruzasvir + uprifosbuvir in HCV GTs 1, 2 & 3
Glecaprevir + pibrentasvir for HCV GTs 1–6?
Sofosbuvir + velpatasvir in HCV
GTs 1–6 with cirrhosis or fibrosis
OBV/PTV/r+DSV+RBV in cirrhotic HCV GT 1b
Ledipasvir/sofosbuvir in teens with HCV GT 1
Please login below to download this issue (PDF)